RenovoRx (NASDAQ:RNXT – Get Free Report) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports. Separately, Weiss Ratings raised RenovoRx from a “sell (e+)” rating to a “sell (d-)” rating in a research note on […]

LendingTree (NASDAQ:TREE – Get Free Report) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday, Wall Street Zen reports. Several other equities research analysts also recently weighed in on the company. Zacks Research downgraded LendingTree from a “strong-buy” rating to a […]

Castle Biosciences (NASDAQ:CSTL – Get Free Report) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a note issued to investors on Saturday, Wall Street Zen reports. Other research analysts have also recently issued research reports about the stock. BTIG Research lifted their price target on […]

Karooooo (NASDAQ:KARO – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports. Several other equities analysts also recently issued reports on KARO. Freedom Capital downgraded shares of Karooooo […]

GH Research (NASDAQ:GHRS – Get Free Report) was downgraded by Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports. A number of other analysts have also recently commented on the company. Cantor Fitzgerald boosted their price objective on GH Research from $35.00 to […]

InnovAge (NASDAQ:INNV – Get Free Report) was downgraded by analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Sunday, Wall Street Zen reports. INNV has been the subject of several other research reports. KeyCorp boosted their price objective on InnovAge from $13.00 to $14.00 and […]

Gyre Therapeutics (NASDAQ:GYRE – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports. A number of other analysts have also recently issued reports on GYRE. Zacks Research raised Gyre Therapeutics from a […]